Sorrento Signs an Exclusive License Agreement with Mabpharm for ACE-MAB to Treat COVID-19

 Sorrento Signs an Exclusive License Agreement with Mabpharm for ACE-MAB to Treat COVID-19

Sorrento Signs an Exclusive License Agreement with Mabpharm for ACE-MAB to TreSorrento Signs an Exclusive License Agreement with Mabpharm for ACE-MAB to Treat COVID-19at COVID-19

Shots:

  • The companies collaborate for the clinical development and commercialization of the ACE-MAB fusion protein that binds to the spike protein of the SARS-CoV-2 virus and treats the COVID-19
  • Sorrento will be responsible for the development and commercialization of ACE-MAB in the NA and EU, while Mabpharm retains rights in the ROW, including the China and Japan
  • ACE-MAB is a bi-specific fusion protein that consists of two functional arms, with one as Ab targeting the spike protein of SARS-CoV-2 with high affinity and other is a truncated ACE2 protein targeting a different epitope of the spike protein

Click here to­ read full press release/ article | Ref: Sorrento | Image: Contract

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post